Recent advances in the understanding and treatment of acute myeloid leukemia.

ABSTRACT: Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.

SUBMITTER: Watts J 

PROVIDER: S-EPMC6081972 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature